Energenesis Biomedical CO.,LTD. (TPE:6657)

Market Cap	6.32B
Revenue (ttm)	7.55M
Net Income (ttm)	-285.26M
Shares Out	88.66M
EPS (ttm)	-3.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,206,076
Average Volume	722,193
Open	76.50
Previous Close	75.60
Day's Range	70.80 - 76.50
52-Week Range	45.90 - 85.60
Beta	0.35
RSI	59.56
Earnings Date	May 9, 2025

About TPE:6657

Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase II clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ENERGI-F708 for asthma treatment; ENERGI-F705 for Parkinson's disease control; ENERGI-F707 for the treatment of mitochondria deficiency; ENERG...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 35
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6657

Financial Performance

In 2024, TPE:6657's revenue was 7.75 million, an increase of 8.26% compared to the previous year's 7.16 million. Losses were -231.08 million, -11.25% less than in 2023.